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Streptococcus agalactiae causes both symptomatic cystitis and asymptomatic bacteriuria (ABU); however, growth characteristics
of S. agalactiae in human urine have not previously been reported. Here, we describe a phenotype of robust growth in human
urine observed in ABU-causing S. agalactiae (ABSA) that was not seen among uropathogenic S. agalactiae (UPSA) strains iso-
lated from patients with acute cystitis. In direct competition assays using pooled human urine inoculated with equal numbers of
a prototype ABSA strain, designated ABSA 1014, and any one of several UPSA strains, measurement of the percentage of each
strain recovered over time showed amarkedly superior fitness of ABSA 1014 for urine growth. Comparative phenotype profiling
of ABSA 1014 and UPSA strain 807, isolated from a patient with acute cystitis, using metabolic arrays of>2,500 substrates and
conditions revealed unique and specific L-malic acid catabolism in ABSA 1014 that was absent in UPSA 807.Whole-genome se-
quencing also revealed divergence in malic enzyme-encoding genes between the strains predicted to impact the activity of the
malate metabolic pathway. Comparative growth assays in urine comparing wild-type ABSA and gene-deficient mutants that
were functionally inactivated for the malic enzymemetabolic pathway by targeted disruption of themaeE ormaeK gene in ABSA
demonstrated attenuated growth of the mutants in normal human urine as well as synthetic human urine containing malic acid.
We conclude that some S. agalactiae strains can grow in human urine, and this relates in part to malic acid metabolism, which
may affect the persistence or progression of S. agalactiae ABU.
Streptococcus agalactiae is a leading cause of infection in new-borns, pregnant women, and older persons with chronic med-
ical illness (1). This organism also causes symptomatic cystitis (2)
and asymptomatic bacteriuria (ABU) (3, 4). These infections have
been associated with diverse patient groups, including pregnant
and nonpregnant women and elderly individuals (2, 5–9). Bacte-
riuria due to S. agalactiae in pregnant women is important due to
the risk for vertical transmission of the bacterium to the newborn
that can lead to life-threatening infections such as central nervous
system invasion and meningitis (10–13). S. agalactiae bacteriuria
of any count during pregnancy is routinely treated with antibiotics
to minimize the risk of vertical transmission to the neonate (14–
17). S. agalactiae bacteriuria has an incidence of between 1.0 and
3.5% in individuals with suspected urinary tract infection (UTI)
(4, 18–21). S. agalactiae bacteriuria loads average between 50,000
and 70,000 CFU ml1 in infected individuals (3), although these
loads are dynamic and have been reported to change dramatically
over just a few hours (2). The significance of S. agalactiae bacteri-
uria in other patient populations and the cost-benefit of universal
treatment for this condition in pregnancy remain unclear (22, 23).
Finally, it is unknown whether S. agalactiae bacteriuria might act
as a reservoir for persistence or contribute to chronic ongoing
infection in the host.
An important fitness trait that contributes to the persistence of
bacteria such as ABU-causingEscherichia coli in the urinary tract is
the ability of the bacteria to grow in human urine. This enables
bacteria such as E. coli to persist in the host by regrowth of non-
voided organisms in residual urine and offers a competitive ad-
vantage independent of urothelial cell binding and inflammation
(24, 25). In addition to E. coli, other organisms have been reported
to grow in urine, including staphylococci (26) and enterococci
(27). To achieve this, the bacteria must endure the low pH of
urine, high urea levels, nutrient limitation, nitrite in mildly acid-
ified urine, and exposure to antimicrobial proteins (e.g., Tamm-
Horsfall protein) and peptides (e.g., cathelicidin). Studies of the
metabolic basis underlying growth in human urine for ABU-caus-
ingE. colihave shown links to transport and degradation pathways
for galacturonate, glucuronide, and galactonate (24), as well as to
synthesis of guanine, arginine, and glutamine (28). Antioxidant
defense mechanisms have also been identified as important for
urine growth of E. coli (29). Russo et al. reported that synthesis of
guanine-dependent products was critical for this phenotype (30).
Arginine metabolism was also shown to contribute to growth of E.
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coli (31). In addition, tolerance to high levels of D-serine, or re-
quirement for this compound, has been linked to survival of
Staphylococcus saprophyticus (26) and E. coli in urine (28), respec-
tively. Iron acquisition byE. coli (32) andEnterococcus faecalis (27)
is also important for this phenotype.
Uropathogenic S. agalactiae (UPSA) strains, isolated from in-
dividuals with acute cystitis and pyelonephritis, were shown in
two prior studies to be incapable of human-urine growth (33, 34).
These organisms adhered to urothelial cells and induced inflam-
matory responses but had no capacity for urine growth, findings
consistent with data published in a prior study of S. agalactiae and
other diverse bacteria (35). The potential of ABU-causing S. aga-
lactiae (ABSA) to grow in human urine has not previously been
investigated. In this study, we report a novel fitness trait of robust
growth of ABSA in human urine, which we did not observe in
multiple UPSA clinical strains analyzed. These findings show that
some S. agalactiae strains are capable of robust urine growth. We
show that this is related, at least in part, to malic acid metabolism.
MATERIALS AND METHODS
Bacterial strains. The ABSA strain used for the initial experiments in this
study was cultured from urine obtained by catheter from an asymptom-
atic 26-year-old pregnant woman undergoing routine screening. Repeat
urine cultures grew pure S. agalactiae at 50,000 CFU ml1, which contin-
ued over a 5-week period, and the woman was diagnosed with ABU. The
strain was designated ABSA 1014. A UPSA isolate, designated UPSA 807,
was used for the initial comparative growth studies. UPSA 807 was cul-
tured from a clean-catch voided urine sample obtained from a 59-year-
old woman who presented with frequency, urgency, hematuria, pyuria,
and bacteriuria of 80,000 CFU ml1. Urinalysis was consistent with a
clinical diagnosis of acute uncomplicated cystitis. S. agalactiae isolates
were routinely identified and serotyped using latex agglutination, as pre-
viously described (2). Details of other isolates used for comparative assays
in subsequent studies are provided in Table 1. This study had ethical
approval from the University of Alabama committee on human experi-
mentation (X070619009) and the Griffith University human ethics com-
mittee (MSC/06/08/HREC), and all work was undertaken in accordance
with the Helsinki Declaration.
TABLE 1 Bacterial strains and plasmids used in this study
Strain or plasmid Relevant characteristic(s)a Reference
Strains
ABSA 1014 26; F; asymptomatic; 50,000b; II; 28 (19); G This study
ABSA 729 69; F; asymptomatic; 30,000b; NTc; 452 (24); G This study
ABSA 834 57; F; asymptomatic; 50,000b; III; 182 (19); G This study
UPSA 807 59; F; Fr/U, GH, P; 80,000; V; 1 (1); G, C, T This study
UPSA 714 89; F; Dys, GH, P; 50,000; III; 17 (17); G, T This study
UPSA 058 77; M; Dys, Fr/U, GH, P; 100,000; Ia; 23 (23); G, T This study
UPSA 008 57; F; Dys, GH; 100,000; V; 1 (1); G, C This study
UPSA 872 69; F; Dys, GH, P; 50,000; Ia; 1 (1); G, T This study
GU2136 E. coli DH5 containing pDI102 This study
GU2293 ABSA 834 containing pDI102 This study
GU2296 ABSA 834maeE (maeE mutant, Cmr) This study
GU2320 GU2296 with pDI110 (maeE complementation plasmid) This study
GU2356 E. coli DH5 containing pDI108 This study
GU2318 E. coli DH5 containing pDI110 This study
GU2436 E. coli DH5 containing pGU2436 This study
GU2446 ABSA 834maeK (maeK mutant, Cmr) This study
GU2468 GU2446 with pDI111 (maeK complementation plasmid) This study
GU2321 WT UPSA 807 with pDI111 (maeK complementation plasmid) This study
GU2319 E. coli DH5 containing pDI111 This study
GU2060 E. coli DH5 containing pLZ12 This study
GU2032 E. coli DH5 containing pHY304
GU2298 E. coli DH5 containing pMSP3545 This study
GU2356 E. coli DH5 containing pMSP3545-aad9 This study
Plasmids
pHY304 ori(Ts), temperature-sensitive shuttle vector, Emr 42
pHY304-aad9 ori(Ts), pHY304 derivative, Sptr This study
pLZ12 E. coli-Streptococcus shuttle vector, Cmr 44
pDI102 pHY304-aad9 derivative, maeE::Cmr construct, Sptr Cmr This study
pGU2436 pHY304-aad9 derivative, maeK::Cmr construct, Sptr Cmr This study
pMSP3545 Emr, Gram-positive bacterial expression vector 47
pDI108 pMSP3545 derivative, Emr cassette replaced with Sptr This study
pDI110 maeE from ABSA 834 cloned into pDI108 using BglII, XhoI
sites
This study
pDI111 maeK from ABSA 834 cloned into pDI108 using BglII, XhoI
sites
This study
a For ABSA and UPSA strains, the characteristics are those of the patient from whom the strain was isolated and are as follows: age (years), gender (F, female; M, male), clinical
presentation (Fr/U, frequency/urgency; GH, gross hematuria; P, pyuria; Dys, dysuria), and bacteriuria count (CFU per milliliter). The characteristics of the strain are as follows:
serotype, sequence type (clonal complex), and antibiotic resistance (G, gentamicin; C, clindamycin; T, tetracycline).
b Bacteriuria count was equal or higher in repeat urine samples.
c NT, nontypeable.
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Human-urine growth assays and culture conditions. For growth as-
says, we used pooled urine collected from six healthy female and male
volunteers who had no recent history of UTI or antibiotic usage (preced-
ing month). Urine was combined in equal volumes, filter sterilized (0.45
m), stored at 4°C, and used within 48 h. Growth of S. agalactiae in urine
and Todd-Hewitt broth (THB) was quantified using colony counts and
turbidity measurements. Duplicate cultures were grown in 200-l vol-
umes in 96-well microtiter plates that were inoculated with approximately
5  103 CFU, which were prepared by washing with sterile phosphate-
buffered saline (PBS; pH 7.4) and back-diluting 1/100,000 from an over-
night culture. Cultures were grown at 37°C with shaking at 200 rpm.
Colony counts were performed using Todd-Hewitt agar (THA), with an-
tibiotic selection as indicated, and optical density at 600 nm (OD600) was
measured to monitor culture turbidity. Growth assays were repeated at
least three to five times in independent experiments using different
batches of pooled urine. Based on the results generated from initial
growth assays, we also performed direct competition assays using mixed
cultures to determine whether ABSA 1014 could outcompete different
UPSA strains in human urine. These assays were based on the differential
susceptibilities of ABSA 1014 and (several) UPSA isolates to clindamycin
and tetracycline, respectively, as listed in Table 1. For competition assays,
ABSA 1014 and any one of several UPSA isolates were mixed at a 1:1 ratio
and incubated in pooled human urine for 72 h. The absolute numbers of
each strain were determined by plating onto selective THA (5 g ml1
clindamycin or 20g ml1 tetracycline; permitting growth of only UPSA
strain) and nonselective THA (permitting growth of both ABSA and
UPSA) to enable the calculation of the relative proportions of each strain
over time.
To examine the growth of bacteria in a defined rich medium, we used
C medium. For this, approximately 5 105 cells were inoculated in 0.1-ml
aliquots and incubated at 37°C. Culture density was monitored using a
POLARstar Omega plate reader (BMG Labtech) with shaking at 500 rpm,
and OD600 was measured every hour. Bacterial growth (CFU per millili-
ter) was quantified after 20 h of culture using colony counts. To examine
the growth of bacteria in a chemically defined minimal medium, we used
M9 medium (36), with minor modifications. Briefly, the following (pre-
sterilized) ingredients were added to 700 ml of autoclaved water: 200 ml of
M9 salts, 2 ml of 1 M MgSO4, 100l of 1 M CaCl2, 0.025% (vol/vol) yeast
extract (from a 10% filter-sterilized stock solution), and 0.1% (vol/vol)
Casamino Acids (from a 20% filter-sterilized stock solution), with exclu-
sion of 0.4% glucose, which was replaced with 40 mM malic acid as a
carbon source where necessary.
PM arrays. A comprehensive comparison of the metabolic profiles of
ABSA 1014 and UPSA 807 was performed using phenotype metabolic
(PM) array fingerprinting (Biolog Inc., Hayward, CA). These arrays tested
the growth of both strains by evaluating 2,500 substrates and physio-
logic exposures, including carbon, nitrogen, and phosphorus utilization;
biosynthetic pathway and nutrient stimulation; osmotic, ionic, and pH
responses; and chemical sensitivity. A complete list of the test conditions
(of PM1-20 arrays) is available at http://www.biolog.com. Additional PM
arrays were also performed on ABSA 834 and ABSA 729. The cultures in
the array plates were incubated at 37°C for 24 to 48 h, and the data were
collected using an OmniLog V1.5 module. We performed pairwise com-
parisons using two independent experiments for the analysis with biolog-
ical duplicates incorporated into each independent experiment.
DNA isolation, genome sequencing, and bioinformatic analysis. To
investigate the genetic basis for the metabolic differences between ABSA
1014 and UPSA 807, we performed whole-genome sequencing followed
by comparative genomic analysis. Genomic DNA was isolated from over-
night cultures of S. agalactiae grown in THB, centrifuged (8,000 g, 10
min), and resuspended in 395 l DNA isolation buffer (50 mM Tris-
HCl, 0.145 M NaCl, pH 7.5) with 5 l mutanolysin (10 U l1). The
cells were incubated for 90 min at 37°C with shaking, followed by the
addition of 154 l DNA isolation buffer, 30 l 10% SDS, 6 l protei-
nase K (20 mg ml1), and 10 l RNase A (20 mg ml1). Following 60
min of incubation at 37°C with shaking, 100 l of 5 M NaCl was added
and mixed. The remaining protocol for DNA isolation used the stan-
dard cetyltrimethylammonium bromide (CTAB) method (36).
Genomic DNA from ABSA 1014, UPSA 807, and six other strains listed
in Table 1 was used to generate 100-bp paired-end reads using the
Illumina HiSeq2000 platform. Reads were then assembled using Velvet
(37), and contigs of 200 bp were annotated using prokka (http:
//www.vicbioinformatics.com/software.prokka.shtml). Genome com-
parisons of syntenic loci were performed using the Artemis Compari-
son Tool (ACT) (38), and comparative genome images were generated
using Easyfig (39). In silico antibiotic and virulence gene profiles were
generated using BLAST (40) and SeqFindR (http://github.com
/mscook/SeqFindR) using both assembled and mapping consensus
modes to allow for read data to be used to identify query sequences that
might not have assembled properly, such as repeat-containing se-
quences. The genomic contexts of tetM, ermA, and ermB were deter-
mined using ACT (38).
Targeted disruption of the MEmetabolic pathway in ABSA. To dis-
rupt the malic enzyme (ME) pathway in ABSA 834, mutations were made
in the maeE (SAG1919) and maeK (SAG1921) genes, encoding the ME
pathway enzyme and sensor kinase, respectively. ABSA 834 was used be-
cause ABSA 1014 was not readily transformable, and the two strains
showed equivalent urine growth phenotypes. Deletion of maeE and maeK
was performed as described elsewhere (41) with modifications. We noted
that ABSA 834 was resistant to erythromycin, so a spectinomycin (Spt)-
resistant derivative of the temperature-sensitive allelic exchange vector
pHY304 (42) was constructed by introducing the Spt resistance gene aad9
from pUCSpec (43) using primers listed in Table S1 in the supplemental
material and termed pHY304-aad9. Briefly, constructs containing 500
bp of sequence flanking the sites for deletion were fused to a chloram-
phenicol (Cm) acetyltransferase (cat) cassette, amplified from pLZ12
(44), by overlapping extension PCR as described previously (45) using
primers listed in Table S1. The upstream reverse and downstream forward
primers for the flanking regions incorporated 5= overhangs complemen-
tary to cat to facilitate three-way gene splicing by overlap extension
(SOEing) PCR using equal amounts of the three amplicons. Primers were
designed based on the S. agalactiae 2603V/R genome. Reaction mixtures
contained 50 ng of DNA, 0.2 mM deoxynucleoside triphosphates
(dNTPs), 1.5 to 4.0 mM MgCl2, 200 nmol of each primer, and 1 unit of
Phusion DNA polymerase (New England BioLabs). Initial denaturation
for 2 min at 98°C was followed by 35 cycles of 10 s at 95°C, 50 s at 65°C, and
30 s/kb at 72°C, with a final extension for 4 min at 72°C. The constructs for
mutation of maeE and maeK were generated by introducing gel-purified
PCR products (QIAquick gel extraction kit; Qiagen) into pHY304-aad9
using restriction sites listed in Table S1 and designated pDI102 and
pGU2436, respectively. E. coli DH5 transformants were screened on LB
agar with Spt (100 g ml1) and chloramphenicol (Cm; 20 g ml1) at
28°C and confirmed by restriction digest, PCR, and sequencing. Follow-
ing electroporation into ABSA 834, as previously described (45, 46),
allelic exchange, and selection of Spts, Cmr (37°C, THA supplemented
with yeast extract [THY] with Cm; 10 g ml1) double crossover
mutants, defective in maeE (strain GU2296) and maeK (strain
GU2446), were obtained using methods essentially the same as de-
scribed elsewhere (41). Mutations were verified by sequencing PCR
products spanning the mutated region (AGRF, Brisbane, Australia).
To ensure that no secondary mutations were present, both mutants
were complemented in trans using wild-type (WT) maeE and maeK
from ABSA 834, cloned into an Spt derivative of pMSP3545 (47),
pDI108, to generate pDI110 (maeE) and pDI111 (maeK) complemen-
tation constructs. These plasmids were transformed into the respective
mutant strains to generate strains GU2320 (maeE-deficient GU2296
complemented with pDI110) and GU2468 (maeK-deficient GU2446
complemented with pDI111).
Measurement of malate in urine. The concentration of malate in
some normal human-urine (NHU) samples and synthetic human urine
Asymptomatic-Bacteriuria-Causing S. agalactiae
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(SHU) was determined using a commercial L-malic acid assay kit (manual
format) (Megazyme International, Bray, Ireland), according to the man-
ufacturer’s instructions.
qRT-PCR expression analysis of the malic enzyme metabolic path-
way inABSA andUPSA. For quantitative real-time reverse transcription-
PCR (qRT-PCR) experiments, assays were performed using bacteria
grown in SHU to minimize variability between different batches of fresh
human urine. For RNA extractions, 12.5-ml cultures of mid-log-phase
ABSA 834 and UPSA 807 were grown in SHU with or without 40 mM
malic acid to cell densities of 105 to 107 CFU ml1. Cultures were added to
5 ml of ice-cold 95% ethanol and 5% (vol/vol) phenol solution and incu-
bated on ice for 30 min to stabilize the RNA and prevent degradation.
Cells were then pelleted (10,000  g, 10 min) and stored at 80°C until
use. Cell pellets were resuspended in Tris-EDTA (TE) buffer containing
100 U mutanolysin (Sigma) and 30 mg ml1 lysozyme (Sigma) and incu-
bated for 1 h at 37°C prior to RNA isolation using the SV Total RNA
isolation kit (Promega), according to the manufacturer’s specifications.
Trace DNA contamination was removed using Turbo DNA-free DNase
(Life Technologies) and confirmed by standard PCR using RNA samples
as the template. Nucleic acids were quantified spectrophotometrically,
and the integrity of RNA samples was analyzed using an Experion auto-
mated electrophoresis platform (Bio-Rad) using RNA StdSens chips, ac-
cording to the manufacturer’s specifications. Total RNA (0.5 to 1g) was
reverse transcribed to cDNA using the Superscript III first-strand synthe-
sis system (Life Technologies) with random hexamers in a final volume of
20 l, according to the manufacturer’s specifications. cDNA was diluted
1:5 with PCR-grade H2O prior to qRT-PCR. Primers were designed using
Primer3Plus software (48) (see Table S1 in the supplemental material) to
amplify products between 80 and 100 bp, with a melting temperature
(Tm) of approximately 60°C, and used at a final concentration of 0.4 M.
The primer binding regions of the target genes maeK, maeE, maeP, maeR,
and rpoB had identical nucleotide sequences in ABSA 834 and UPSA 807
(data not shown).
Real-time quantification of transcripts was done using the Quantifast
SYBR green kit (Qiagen) and a LightCycler 480 II real-time PCR de-
tection system (Roche), according to the manufacturer’s specifica-
tions. All reactions were performed in triplicate, and transcript
amounts were quantified from three RNA preparations that were iso-
lated from independent biological replicates. Standard curves and am-
plification efficiencies were determined using serially diluted (10-fold)
genomic DNA. Expression values were normalized using the rpoB gene
of S. agalactiae, which encodes RNA polymerase 	 subunit (SAG0160).
Relative fold change values were calculated using amplification effi-
ciencies, as described previously (49). All experiments conformed to
the Minimum Information for Publication of Quantitative Real-Time
PCR Experiments (MIQE) guidelines (50). For experiments compar-
ing pH levels, C medium (pH 7.5) was used as a background medium
as described previously (51). C medium containing either 100 mM
morpholineethanesulfonic acid (MES) or 40 mM malic acid was ad-
justed to pH 6.0 and filter sterilized prior to use.
Murine model of UTI. Female C57BL/6 mice (8 to 10 weeks) were
purchased from the Animal Resources Centre (Canning Vale, WA, Aus-
tralia). The murine model of UTI based on transurethral inoculation (52)
was used for this study. Briefly, an inoculum of 40 l, containing 5 108
CFU of bacteria in PBS, was instilled into the bladder using a 1-ml syringe
attached to a catheter. Groups of 8 to 10 mice were euthanized after 24 h,
and bladders were collected and homogenized in sterile PBS for colony
counts on THB agar. The experiment was repeated independently. All
procedures were approved by and conducted within the guidelines of the
Griffith University Animal Research Ethics Committee (approval no.
MSC/14/08/AEC).
Statistical analysis. Bacterial growth was compared using analysis of
area under the curve (AUC) and Student’s t test. The mean numbers of
bacterial CFU per milliliter were compared using an independent-sample
t test. All statistical analyses were carried out using IBM SPSS statistics
software (version 20.0) and GraphPad Prism software package 5.0. P val-
ues of
0.05 were considered significant.
RESULTS
Growth of ABSA andUPSA in human urine. Initial examination
of two different UPSA strains from patients with cystitis (33) and
other S. agalactiae isolates from a prior study (34) showed that
these organisms grew very poorly in human urine, a finding that
was consistent with another previous study (35). Based on these
data, we tested and exposed a novel phenotype of efficient growth
in human urine for ABSA 1014 that was not observed in several
UPSA strains, including UPSA 807 (Fig. 1A). The average gener-
ation time of ABSA 1014 was 170 min (calculated between 0 and
36 h), compared to UPSA 807 and other UPSA strains that grew
poorly, with generation times of 600 min (two-sample two-
tailed t test, P 
 0.001). Subsequent analyses of several other
UPSA and ABSA strains that were isolated from different patients
with acute UTIs and individuals with ABU, respectively, showed
similar urine growth patterns (Fig. 1B). Thus, these data establish
that multiple ABSA strains can grow robustly in human urine, in
contrast to UPSA strains that grow poorly in urine.
The rapid doubling time of ABSA 1014 in human urine com-
pared to UPSA indicated that this strain might outcompete UPSA
strains in direct competition assays. In urine that was inoculated
with equal numbers of ABSA 1014 and UPSA 807 organisms, or
any one of several other UPSA strains (mixed 1:1 at start of assay),
the percentage of each strain recovered over time showed the
markedly superior fitness of ABSA 1014 for human-urine growth
compared to the UPSA strains (Fig. 1C). In these assays, ABSA
1014 constituted 50% of the mixed population at t  0 h
but 90% of mixed cultures after 36 h (P 
 0.001, paired two-
tailed t test). The superior growth phenotype of ABSA 1014 was
urine specific because all of the strains had similar log-phase
growth rates in THB, as illustrated in Fig. 1D. Thus, ABSA 1014
outcompetes multiple UPSA strains for rapid growth in human
urine through a urine-specific growth trait evidenced by an ab-
sence of any general growth defect in UPSA strains detectable
using standard THB laboratory medium.
Metabolic profiling of ABSA 1014 and UPSA 807 using PM
arrays. We next undertook a comprehensive comparison of the
core physiological properties of ABSA 1014 and UPSA 807 using
PM arrays to gain insight into the metabolic potential of these
strains. The arrays uncovered only a few metabolic differences
between the strains; in fact, there were a total of only four gained
phenotypes in ABSA 1014. These were efficient utilization of D,L-
malic acid and L-malic acid and resistance to sodium arsenate and
cadmium chloride. In addition, there were several phenotypes
that were absent in ABSA 1014 compared to UPSA 807, including
resistance to macrolides and lincomycin. A complete list of these
metabolic profiles is provided in Table 2, which represents all of
the metabolic phenotype differences that were observed between
the two strains. Subsequent array profiling of two additional
ABSA strains, 834 and 729, showed that these strains also exhib-
ited phenotypes of efficient utilization of D,L-malic acid and L-
malic acid compared to UPSA 807 (data not shown). A gene en-
coding a putative malate oxidoreductase has been annotated in
the S. agalactiae 2603V/R reference genome; however, the ME
pathway has not been characterized in S. agalactiae to date. Malic
acid metabolism is typically associated with an operon comprising
genes encoding a malate oxidoreductase enzyme (maeE), a per-
Ipe et al.
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mease/transporter (maeP), a transcriptional regulator (maeR),
and/or an accessory membrane-anchored sensor kinase (maeK)
(53). Bacterial MEs catalyze the oxidative decarboxylation of
malate to pyruvate and CO2 (54), which underpins malolactic
fermentation. While there is some evidence that MEs contribute
to energy generation and bacterial survival at low pH, a role for
MEs in bacterial growth in urine has not previously been investi-
gated. Therefore, we examined the ME pathway in ABSA 1014 and
UPSA 807 using a combination of genome sequencing, bioinfor-
matics, and functional analyses.
Draft genome assembly and analysis ofmae genes. The draft
assembled genomes of ABSA 1014 and UPSA 807 showed the
presence of the mae gene cluster in both strains (Fig. 2). The mae
gene clusters from ABSA 1014 and UPSA 807 shared identical
FIG 1 (A) Robust growth of ABSA 1014 in urine contrasts with poor growth of UPSA strains 807, 714, and 058. (B) High-growth phenotypes of additional ABSA
strains 729 and 834 in human urine compared to UPSA strains 008 and 872. (C) Direct competition assays revealed markedly superior fitness of ABSA 1014 for
growth in urine versus UPSA 807, 714, 008, and 872; *, OD600 of ABSA 1014-UPSA 807 coculture shown; results were similar to those for other cocultures. (D)
Robust growth of all strains in THB showed no general growth defect of UPSA strains. Data are pooled results of at least three to five independent assays and show
mean values standard errors of the means.
TABLE 2 Metabolic profile of ABSA 1014 compared to UPSA 807, derived from PM array, and genotype relating to phenotype (substrate or
molecule), determined using draft genome assemblies
Metabolic phenotype
gained in ABSA 1014
Activity level
(OmniLog
units) Substrate or molecule
Phenotype relating to substrate or
molecule
Genotype relating to substrate
or molecule
Carbon utilization 114 D,L-Malic acid Carbon source, carboxylic acid maeK frameshift in UPSA 807
83 L-Malic acid Carbon source, carboxylic acid maeK frameshift in UPSA 807
Resistance 99 Sodium arsenate Toxic anion, phosphate analog ICEsde3396 in ABSA 1014
305 Cadmium chloride Toxic cation ICEsde3396 in ABSA 1014
Sensitivity 148 Poly-L-lysine Membrane, detergent, cationic NDa
207 Alexidine Membrane, e transport, biguanide ND
253 Lincomycin Protein synthesis, lincosamide Tn6002 in UPSA 807
550 Oleandomycin Protein synthesis, macrolide Tn6002 in UPSA 807
465 Troleandomycin Protein synthesis, macrolide Tn6002 in UPSA 807
207 Spiramycin Protein synthesis, macrolide Tn6002 in UPSA 807
a ND, not determined.
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structural organization with the homologous mae cluster from
Lactobacillus casei BL23 (55). Notably, however, a frameshift mu-
tation in a poly(A) sequence at the 5= end of maeK of UPSA 807
was identified (Fig. 2). This mutation would lead to the produc-
tion of a truncated nonfunctional protein (using an alternative
downstream ATG start codon) that lacks the first 19 amino acids
corresponding to part of the signal peptide of this membrane pro-
tein. The mutation in UPSA 807 (Fig. 2) was confirmed by PCR
using primers uppS-F and galE-R (see Table S1 in the supplemen-
tal material) and sequencing of the entire mae gene cluster from
ABSA 1014 and UPSA 807 (accession numbers KU061060 to
KU061067). Further sequence comparisons showed the presence
of homologous gene clusters in all complete genomes of S. agalac-
tiae available in the databases. We observed equivalent structural
organizations in all strains but noted several other unique disrup-
tions, in particular in all non-human-associated strains (SA20-06,
ILRI112, ILRI005, 2-22, and 09mas018883). The details of these
disruptions, and their presence in the S. agalactiae strains available
in the databases, are illustrated in Fig. 3.
Growth of UPSA 807 in urine following maeK complemen-
tation in trans. To ascertain whether UPSA could grow in human
urine in the presence of a fully functioning mae gene cluster, we
cloned functional maeK from ABSA 834 into plasmid pDI108,
derived from pMSP3545 (47), and transformed this into UPSA
807. Growth experiments in pooled NHU containing 40 mM
malic acid demonstrated that the growth of WT UPSA 807 was
significantly increased following genetic complementation with
maeK (Fig. 4; area under the curve [AUC] analysis, 36 h to 72 h,
P
 0.01). The two strains grew similarly in THB with equivalent
growth curves over the same time course (data not shown).
Growth of ABSA and UPSA in synthetic and normal urine
containing defined malate levels. We retrospectively measured
the concentrations of malate and creatinine in several of the nor-
mal human-urine samples used for growth assays. The malate
concentrations ranged between 0.2 mM and 8 mM (limit of
detection of assay, 0.2 mM), and creatinine ranged between 28 and
211 mg dl1 (ratio of malic acid to creatinine ranged between 0
and 1,056 g mg1). Therefore, we analyzed whether the growth
of ABSA and UPSA strains would differ in a synthetic medium
that contained a defined amount of malate. For this, we used SHU
as defined in previous studies (56–58) supplemented with 40 mM
malic acid, a concentration consistent with prior studies that have
used 30 to 50 mM malic acid in vitro (51, 53–55, 59–62). We
observed that the growth of ABSA 834 and ABSA 729 was signifi-
cantly higher than the growth of UPSA 058 and UPSA 714 in SHU
(Fig. 5A), irrespective of the strain pair comparison and regardless
of the presence of 40 mM malic acid (Fig. 5B). Notably, however,
chemical supplementation with 40 mM malic acid significantly
increased the growth of both ABSA strains and UPSA 058 and
UPSA 714 (Fig. 5B, AUC analysis, 24 h to 72 h, P 
 0.01); these
strains have an intact mae gene cluster (UPSA 058) and a single
frameshift mutation that is predicted to alter only the last three
amino acids at the C terminus of the protein (and unlikely to
disrupt function) (UPSA 714), respectively (Fig. 3).
We also compared the growth rates of WT ABSA 834 in two
defined concentrations of malic acid, 8 mM and 40 mM, in NHU
to explore any dose-dependent effects and contrasted these effects
with the urine growth curves of ABSA 729, UPSA 807, and UPSA
714 based on the mae background of these strains (Fig. 3). These
results showed that the growth of ABSA strains and UPSA 714
(harboring a predicted functional ME pathway) was significantly
FIG 2 Organization of the mae locus in ABSA 1014 and UPSA 807. In UPSA 807, maeK contains a single-base-pair deletion in the homopolymeric tract at
position12 at the proximal 5= end. A potential alternative start codon can be found downstream at position52.
FIG 3 Mutations in mae genes in ABSA and UPSA strains in this study (aster-
isks with accession numbers indicate data from Bioproject identifier PRJEB28
37) and in the complete genomes of S. agalactiae strains available in GenBank.
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increased at 24 h in the presence of the higher concentration of
malic acid (40 mM) (see Fig. S1 in the supplemental material;
Student’s t test, P
 0.01). The growth of UPSA 807 (harboring a
predicted nonfunctional ME pathway) was not augmented by the
presence of either concentration of malic acid (see Fig. S1). Thus,
growth of ABSA in synthetic and normal urine increases with
larger amounts of malic acid, and an intact ME pathway is re-
quired for this dose-dependent effect on growth.
In experiments using M9 minimal medium in which glucose
was replaced with 40 mM malic acid as a carbon source, we ob-
served significantly higher growth of ABSA 834 and 729 and UPSA
714 and 058 (both harboring predicted functional ME pathways)
than of UPSA 807. ABSA 834 was unable to grow in M9 minimal
medium in the absence of malic acid, but supplementation with 40
mM malic acid enabled growth to a cell density of 109 CFU ml1.
Other ABSA and UPSA strains with intact mae gene clusters
showed similar enhanced growth in M9 medium supplemented
with malic acid compared to M9 medium alone (see Fig. S2 in the
supplemental material). These results demonstrate that the pres-
ence of malic acid as a carbon source can support robust growth of
S. agalactiae in a minimal medium.
Mutation in maeK or maeE attenuates the growth of ABSA
834. We inactivated the ME pathway in ABSA 834 by generating
an isogenic maeK-deficient mutant and performed comparative
urine growth assays. We used ABSA 834 because we found that
ABSA 1014 was not easily transformable, and ABSA 834 exhibited
urine growth properties equivalent to those of ABSA 1014. WT
ABSA 834 grew significantly better than its maeK-deficient mu-
tant in SHU and pooled NHU containing 40 mM malic acid (AUC
analysis, 12 h to 72 h, P
 0.01) (Fig. 6). Complementation of the
maeK-deficient mutant in trans using plasmid pDI111 (Table 1)
restored the growth of the mutant in SHU (Fig. 6A) but only
partially in NHU (Fig. 6B) (AUC analysis, 24 h to 48 h, P
 0.05).
WT ABSA 834 also grew significantly better than the maeE- and
maeK-deficient mutants in NHU in the absence of supplemental
malic acid; however, growth rates of WT ABSA 834 did not differ
between aerobic and microaerobic conditions or between shaking
and static conditions (data not shown).
To define the requirement for maeE for urine growth, we gen-
erated a maeE-deficient mutant in ABSA 834. The results of
growth assays comparing the WT ABSA 834 and its ABSA
834maeEmutant derivative in SHU and pooled NHU, both con-
taining 40 mM malic acid, are shown in Fig. 7. The ABSA
834maeEmutant was significantly attenuated for growth in both
SHU and NHU compared to WT ABSA 834. Complementation of
the maeE-deficient mutant in trans using plasmid pDI110 (Table
1) significantly restored the growth of the mutant in SHU (Fig.
7A) (AUC analysis, 24 h to 72 h, P 
 0.01) and NHU (Fig. 7B)
(AUC analysis, 24 h to 72 h, P 
 0.01). In these experiments,
measurement of the amount of L-malic acid that was present in the
growth medium at the start of the assay (t  0 h) and at 72 h
showed a 65 to 70% reduction in malic acid concentration after 72
h of growth of WT ABSA 834 but no significant reduction in malic
acid concentration in cultures of the ABSA 834maeE mutant.
Together, these data show that functional maeK and maeE are
FIG 4 Growth of WT UPSA 807 in pooled normal human urine (NHU)
containing 40 mM malic acid and comparison with a maeK genetically com-
plemented strain. Genetic complementation with maeK in trans significantly
increased the ability of UPSA 807 to grow in 5-ml NHU cultures containing 40
mM malic acid (area under the curve [AUC] analysis, 36 h to 72 h, P
 0.01).
Data are pooled results of at least three to five independent assays and show
mean values standard errors of the means.
FIG 5 Growth of WT ABSA 834, ABSA 729, UPSA 058, and UPSA 714 in 5-ml
cultures of synthetic human urine (SHU) (A) and SHU containing 40 mM
malic acid (B). Growth of the ABSA strains was significantly higher than that of
UPSA strains (AUC analysis, 24 h to 72 h, P
 0.01). Chemical supplementa-
tion with 40 mM malic acid significantly increased the growth of UPSA 058
and UPSA 714 compared to growth conditions without malic acid (AUC anal-
ysis, 24 h to 72 h, P 
 0.01; comparisons were UPSA 058 without and with
malic acid and UPSA 714 without and with malic acid). Data are pooled results
of at least three to five independent assays and show mean values standard
errors of the means.
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required for optimal growth of ABSA in urine in the presence of
malate.
Expression of mae genes in ABSA and UPSA during growth
inmedium containingmalate. The transcription of all four genes
that comprise the mae gene cluster (maeK, maeE, maeP, and
maeR) was examined by qRT-PCR in ABSA 834 and UPSA 807
grown in SHU with and without 40 mM malic acid. In these ex-
periments, ABSA 834 significantly upregulated the transcription
of maeE and maeP (10-fold) in response to malic acid during
growth in SHU (Fig. 8). Strikingly, and in contrast to ABSA 834,
the transcription of these genes in UPSA 807 was unaffected by the
presence of malic acid during growth in SHU (Fig. 8). We did not
detect any significant changes (2-fold) in the expression of ei-
ther maeK or maeR in either ABSA 834 or UPSA 807 when com-
paring relative transcript abundances following growth in SHU in
the presence or absence of malic acid. However, the absolute tran-
script levels of maeK and maeE did differ between ABSA 834 and
UPSA 807 following growth in SHU in the presence of 40 mM
malic acid (see Fig. S3 in the supplemental material). Together,
these data show that there is a significant mae transcriptional re-
sponse in ABSA 834, but not in UPSA 807, during growth in SHU
containing malic acid.
We also examined whether acidic pH is sufficient to induce
mae gene transcription in ABSA 834, independently of malic acid.
We found that a shift in pH of 1 unit (6.5 to 5.5) induced tran-
scription of maeE and maeP in SHU in the presence of malic acid
(see Fig. S4A in the supplemental material), indicating an addi-
tional level of induction linked to pH. Further, using nutrient-rich
C medium supplemented with either malic acid or MES, in an
approach similar to a previous study (51), we compared transcrip-
tion levels of maeE and maeP at pH 7.5 and pH 6.0. We observed
that the mae genes were induced independently of malic acid as a
major carbon source in the growth medium. In these assays (cul-
ture densities, 5 108 to 2 109 CFU ml1 after 20 h), there were
approximately 32- and 14-fold increases in maeE and maeP, re-
spectively, in the presence of malic acid at pH 6.0 (see Fig. S4B),
FIG 6 Growth of WT ABSA 834, ABSA 834maeK, and ABSA 834maeKC
(superscripted “C” indicates complemented mutant strain) in synthetic hu-
man urine (SHU) (A) and pooled normal human urine (NHU) (B), both
containing 40 mM malic acid (5-ml cultures). Growth of the WT was signifi-
cantly higher than that of the ABSA 834maeK mutant (AUC analysis, 12 h to
72 h, P 
 0.01). Complementation in trans using plasmid pDI111 partially
restored the growth of the mutant in SHU (AUC analysis, 12 h to 72 h, P 

0.01). Data are pooled results of at least three to five independent assays and
show mean values standard errors of the means.
FIG 7 Growth of WT ABSA 834, ABSA 834maeE, and ABSA 834maeEC
(superscripted “C” indicates complemented mutant strain) in synthetic hu-
man urine (SHU) (A) and pooled normal human urine (NHU) (B), both
containing 40 mM malic acid (5-ml cultures). Growth of the WT was signifi-
cantly higher than that of the ABSA 834maeE mutant (AUC analysis, 24 h to
72 h, P 
 0.01). Complementation in trans using plasmid pDI110 partially
restored the growth of the mutant (AUC analysis, 24 h to 72 h, P
 0.01). Data
are pooled results of at least three to five independent assays and show mean
values standard errors of the means.
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consistent with our experiments described for SHU. In addition,
there were approximately 11- and 5-fold increases in maeE and
maeP, respectively, in medium containing MES at pH 6.0, which
was devoid of malic acid. Thus, consistent with a previous study
(51), we observed that acidic conditions, in the absence of malic
acid, are sufficient to induce the transcription of the mae genes in
ABSA.
ABSA and UPSA colonization in vivo using a murine model
of UTI. We initially analyzed colonization of ABSA 1014 and
UPSA 807 in mice to compare the relative fitnesses of these strains
in vivo. There was a significant difference in the recovery of ABSA
1014 and UPSA 807 from the bladder of mice at 24 h following
infection. ABSA 1014 was recovered in significantly higher num-
bers than UPSA 807 (Fig. 9A) (1.70  105 CFU of ABSA 1014
versus 5.37 104 CFU of UPSA 807, P 0.004, Mann-Whitney U
test). We also compared the colonization levels of ABSA 834 and
its isogenic maeE-deficient mutant to study the effect of a non-
functional ME pathway on in vivo colonization. There was a sig-
nificant difference in the recoveries of WT ABSA 834 and the
ABSA 834maeE mutant from the bladder at 24 h following in-
fection, with 65% fewer mutant bacteria recovered (Fig. 9B)
(3.47  105 CFU of WT ABSA versus 1.23  105 CFU of ABSA
834maeE, P  0.042, independent-sample t test). Thus, ABSA
1014 colonizes the urinary tract of mice significantly better than
UPSA 807 following experimental infection, and a functional ME
pathway in ABSA 834 contributes significantly to this phenotype.
DISCUSSION
The principal aim of this study was to determine whether ABSA
might be capable of urine growth, which is a trait of some ABU-
causing E. coli strains (24, 25, 32). The central findings of this
study are that (i) ABSA can grow efficiently in human urine, in
contrast to UPSA strains tested to date that grow poorly; (ii) ABSA
1014 (and 834 and 729) can utilize malic acid in contrast to UPSA
807; (iii) malic acid utilization in ABSA correlates with an intact
mae locus; and (iv) in ABSA, a functionally intact ME pathway is
required for robust growth in human urine and affords activity for
malic acid catabolism that takes place during urine growth. More
broadly, the literature shows that ABU-causing E. coli strains bind
poorly to urothelial cells and fail to stimulate a strong proinflam-
matory response during persistent infection (24, 25, 32, 63–65). In
contrast, uropathogenic bacteria adhere to urothelial cells and in-
duce inflammation (34, 66, 67). Prior studies showed that UPSA
can adhere to urothelial cells efficiently; however, UPSA grew
poorly in urine (33, 34), consistent with a report by Stamey and
Mihara (35). In this study, the finding that ABSA can utilize urine
for robust growth sheds light on how this organism may interact
with the host during UTI, and this could influence the persistence
of S. agalactiae ABU in some individuals. This hypothesis and the
ability of ABSA strains to adhere to urothelial cells will be areas for
future investigation.
In defining the phenotypic ABSA metabolome, and comparing
this with genetic and mutational analyses, this study provides key
insight into the mechanisms underlying urine growth for S. aga-
lactiae. The inability of UPSA 807 to grow in urine correlated with
a metabolic deficiency of malic acid catabolism, as revealed using
PM arrays. Genome-sequence comparisons with ABSA 1014
highlighted the predicted nonfunctional ME pathway in UPSA
807. Crucial point mutations predicted to impact the functional
integrity of the ME pathway in S. agalactiae were confirmed in
multiple UPSA strains by comparative analyses. In addition, the
targeted generation of a maeE-deficient ABSA mutant showed
that inactivation of the ME pathway significantly restricts the
growth in an otherwise “robust” strain in NHU and SHU contain-
ing malic acid; thus, a functionally active ME pathway contributes
to the robust urine growth phenotype in ABSA. Genetic comple-
mentation of UPSA 807 with functional maeK in trans conferred
an ability of this strain to grow in human urine containing malic
acid. To our knowledge, this is the first description of a role for a
bacterial ME pathway in human-urine utilization. Interestingly,
the presence of a functionally intact ME pathway in two UPSA
strains that grew poorly in urine (UPSA 714 and 058) implies that
ME divergence is not the sole metabolic distinction between all
ABSA and UPSA strains underlying differential urine growth. In
other words, growth differences in all ABSA and UPSA strains are
not solely explained by differences in malic acid metabolism, and
we predict that these differences are likely to be influenced by
other, unknown factors. Urine growth differences between some
strains, for example, could be influenced by factors other than
differences in malic acid metabolism, such as resistance to D-ser-
FIG 8 Relative expression of maeK, maeE, maeP, and maeR in ABSA 834 and
UPSA 807 following growth in 12.5-ml cultures of synthetic human urine
(SHU). qRT-PCR data show fold change relative to the reference rpoB in the
presence and absence of 40 mM malic acid. Error bars represent standard
deviations between three independent biological replicates.
FIG 9 (A) Colonization in the murine UTI model demonstrates significantly
higher recovery of ABSA 1014 than of UPSA 807 (*,P 0.004, Mann-Whitney
U test, based on non-normally distributed data according to Shapiro-Wilk
test; bars represent medians and show interquartile ranges). (B) Significantly
higher recovery of WT ABSA 834 than of ABSA 834maeE is shown (*, P 
0.042, independent-sample t test, normally distributed data according to Sha-
piro-Wilk test; bars represent means standard errors of the means). Data are
presented as pooled results of two independent experiments each containing 8
to 10 mice per group. The limit of detection of the assay was 50 CFU ml1 for
bladder homogenates.
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ine (26), metabolism of guanine (30), and iron acquisition (32).
More broadly, chronic infection by uropathogenic E. coli (UPEC)
is compounded by multiple virulence mechanisms, including ad-
hesion, invasion of uroepithelial cells, evasion of host immune
responses, intracellular survival, and replication in host cells, as
reviewed elsewhere (67–69). Thus, the impact of virulence on per-
sistence of UPSA in the urinary tract, independent of growth in
urine, represents an area of future research for this uropathogen.
Other studies using transcriptional profiling would also be of in-
terest to explore the full gamut of gene activation pathways at play
during ABSA growth in urine, beyond malic acid metabolism.
L-Malic acid is a common organic acid in fruits and vegetables,
is synthesized in the kidney, and can be present in human urine
(http://www.hmdb.ca/metabolites/HMDB00156) along with py-
ruvic acid (70), from which it can be derived. Its concentration in
urine is dramatically affected by dietary intake (71). In bacteria, a
metabolic signature of L-malic acid utilization is often related to
functional expression of the ME pathway, as characterized in Lac-
tobacillus casei (55) and Enterococcus faecalis (54); however, bac-
teria can metabolize malic acid through different pathways; in E.
coli and Bacillus subtilis, this is controlled by a two-component
system (72, 73); in lactic acid bacteria, including L. casei (55) and
Streptococcus mutans (60, 61), L-malic acid is converted to L-lac-
tate by malolactic enzyme. E. faecalis (54, 74), Streptococcus bovis
(75), and L. casei (55) metabolize L-malic acid to pyruvate using
the ME pathway. Oral streptococci degrade malic acid to create an
alkaline environment that may protect against acid damage and
oxidative and starvation stress (60–62). Utilization of malic acid
via the ME pathway may therefore enable an organism to survive
and grow at a lower pH (55). In our study, growth of ABSA in the
acidic-pH environment of human urine (pH 5.5 to 6.2) required
an intact ME pathway. A recent study on group A streptococcus
(51) identified malate degradation as a link between pH and vir-
ulence. Our findings of increased transcriptional activity of the
maeE and maeP genes in ABSA in response to malate are also
consistent with the response of group A streptococcus (51).
Uropathogenic bacteria, including E. coli and enterococci, can
utilize human urine for growth (27, 28, 35). Urinary components,
including D-serine, guanine, and small peptides, can influence the
growth of these organisms in urine (76, 77). Prior to the current
study, the compounds in urine that S. agalactiae may use to grow
have not been described. The finding that ABSA can metabolize
L-malic acid in urine is interesting; this compound is a widespread
organic acid found at high levels in currants, rhubarb, green ap-
ples, and grape musts (61, 78); pumpkin fruits (79); and wine (71)
and is naturally excreted in human urine (70, 71, 80); its concen-
tration varies dramatically depending on dietary intake. Other
variable components in human urine include glucose (51, 53, 55,
70) and fructose, which may inhibit metabolic pathways, includ-
ing the ME pathway, as reported in Streptococcus lactis (81), E.
faecalis (74), and L. casei (55). Considering the various levels of
these components in human urine, we used a standardized SHU
medium to compare the growth rates of WT and mutant ABSA
under controlled growth conditions. Synthetic medium to model
human urine has been used in many studies to examine bacterial
growth, although the compounds that bacteria utilize for growth
remain undefined in most cases. The activity of the ME pathway
also depends on divalent cofactors such as Mn2 or Mg2 (82).
The requirement for cofactors in ABSA ME metabolism in urine
remains to be defined.
The findings of the current study can also be compared more
broadly to the literature in terms of implications for pathogenesis
and infection in UTIs. Recent data from Kline et al. showed that
the presence of S. agalactiae in the urinary tract in mice could
predispose the host to other uropathogenic bacteria such as E. coli
(83). Our findings suggest that ABSA strains that colonize urine
more efficiently may have the potential to modify the progression
of UTIs due to other causal organisms in some individuals. Fur-
thermore, S. agalactiae has the ability to modulate host immune
responses in the bladder, and studies to define potential differ-
ences between ABSA and UPSA in terms of immune modulation
will now be important. More broadly, there may be potential di-
etary implications of the findings reported here, for example, for
women during pregnancy. Establishing the ME pathway and the
presence of malic acid as important for growth of some S. agalac-
tiae strains in human urine points to a need for more studies on
the effect of diet on urinary malate and the potential link between
diet, malate, and ABU. Whether other bacterial species can utilize
malic acid for urine growth is another interesting question to be
addressed.
Recent studies on the genomics and virulence of S. agalactiae
have identified a range of disease/host-associated genetic traits
(84–87) and mechanisms of virulence (88–90). In this sense, we
hypothesize that there is likely to be a spectrum of genotypes,
phenotypes, and virulence strategies used by UPSA and ABSA to
colonize and cause infection in the urinary tract; this would par-
allel knowledge for UPEC (67). While our data provide initial
insight into the relationship between UPSA and ABSA, there are
no data to support a concept of mutual exclusivity. Other findings
in this study, such as the unique disruptions in the mae gene clus-
ter in non-human-associated S. agalactiae strains, highlight the
need for future investigation of mae genes in different host envi-
ronments. Finally, the discovery of a novel phenotype of robust
growth in human urine by ABSA, and the ability of ABSA to utilize
malic acid in urine, has implications for our overall understanding
of the mechanisms used by this organism to colonize the urinary
tract and provides the basis for further studies.
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